PT987251E - 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp - Google Patents

4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp

Info

Publication number
PT987251E
PT987251E PT99307264T PT99307264T PT987251E PT 987251 E PT987251 E PT 987251E PT 99307264 T PT99307264 T PT 99307264T PT 99307264 T PT99307264 T PT 99307264T PT 987251 E PT987251 E PT 987251E
Authority
PT
Portugal
Prior art keywords
cholesterol
inhibitors
levels
ldl
prodrug
Prior art date
Application number
PT99307264T
Other languages
English (en)
Inventor
Stephen Wayne Goldstein
Michael Raymond Makowski
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT987251E publication Critical patent/PT987251E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99307264T 1998-09-17 1999-09-14 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp PT987251E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10072998P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
PT987251E true PT987251E (pt) 2004-10-29

Family

ID=22281233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99307264T PT987251E (pt) 1998-09-17 1999-09-14 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp

Country Status (10)

Country Link
US (2) US6140342A (pt)
EP (1) EP0987251B1 (pt)
JP (1) JP3626641B2 (pt)
AT (1) ATE267172T1 (pt)
BR (1) BR9904141A (pt)
CA (1) CA2282183C (pt)
DE (1) DE69917400T2 (pt)
DK (1) DK0987251T3 (pt)
ES (1) ES2220013T3 (pt)
PT (1) PT987251E (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
DE10035352A1 (de) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
KR20040015746A (ko) * 2001-06-21 2004-02-19 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제
SK15742003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2003063868A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2003063833A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ES2263015T3 (es) * 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CN101342162A (zh) * 2003-09-26 2009-01-14 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
WO2006009819A1 (en) * 2004-06-18 2006-01-26 Array Biopharma Inc. Inhibitors of cholesteryl ester transfer protien
BRPI0514051B1 (pt) * 2004-08-04 2014-07-22 Nippon Kayaku Kk Composto derivado de quinolina que compreende o mesmo como ingrediente ativo, inseticida, método e uso destes no controle de pragas de insetos na agricultura e horticultura
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
CN101146776A (zh) 2005-02-24 2008-03-19 米伦纽姆医药公司 治疗炎性疾病的pgd2受体拮抗剂
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7678818B2 (en) * 2006-02-07 2010-03-16 Hoffmann-La Roche Inc. Anthranilamide and 2-amino-heteroarene-carboxamide compounds
WO2008009435A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
UA96942C2 (uk) * 2006-07-20 2011-12-26 Новартис Аг Похідні амінопіперидину як інгібітори бпхе (білка-переносника холестерилового ефіру)
PT2463282E (pt) 2007-11-05 2013-11-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
KR20100093103A (ko) 2007-12-03 2010-08-24 노파르티스 아게 고지혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃετρ 억제제로서의 1,2-이치환된 4-벤질아미노-피롤리딘 유도체
WO2009071099A1 (en) * 2007-12-05 2009-06-11 Aarhus Universitet Elevation of the plasma hdl-cholesterol level
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
DK3464336T3 (da) 2016-06-01 2022-05-09 Athira Pharma Inc Forbindelser
CN114853670B (zh) * 2022-05-23 2023-11-21 沈阳药科大学 含有酰胺基团的喹啉类化合物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
EP0987251B1 (en) 2004-05-19
JP2000191645A (ja) 2000-07-11
DE69917400D1 (de) 2004-06-24
BR9904141A (pt) 2000-09-12
DE69917400T2 (de) 2005-05-19
EP0987251A1 (en) 2000-03-22
DK0987251T3 (da) 2004-09-27
CA2282183C (en) 2006-08-08
ATE267172T1 (de) 2004-06-15
US6362198B1 (en) 2002-03-26
CA2282183A1 (en) 2000-03-17
ES2220013T3 (es) 2004-12-01
JP3626641B2 (ja) 2005-03-09
US6140342A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
PT987251E (pt) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores de cetp
UA70960C2 (uk) 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер
BR9904162A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas
BG105428A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
WO2004085401A8 (en) 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
CA2207574A1 (en) Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
CA2507465A1 (en) Phenyl substituted piperidine compounds for use as ppar activators
MXPA05012570A (es) Derivados de tetrahidroisoquinolina como activadores de ppar-a.
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
ATE357453T1 (de) Comt-inhibitoren
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
WO1999025712A1 (fr) Nouveaux composes d'amide et medicaments contenant ces derniers
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
AU8998298A (en) Compounds having (2.2.1)bicyclo skeleton
EP1857444A1 (en) Tetrahydroisoquinoline compound and medicinal use thereof
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
AU2068895A (en) Dl- di- or tri-hydroxyphenylglycine alkyl esters for the treatment of inflammatory and allergic conditions
DE69303333D1 (de) Substituierte Benzoate-Derivate
TH41636A (th) อนุพันธ์ n-อัลเคโนอีลเฟนนิลอะลานีน